Recursion Pharmaceuticals, Inc.'s REC-994 was able to show positive safety/tolerability data for the treatment of Cerebral Cavernous Malformation, along with a trend towards improvement.End-of-phase 2...
Source LinkRecursion Pharmaceuticals, Inc.'s REC-994 was able to show positive safety/tolerability data for the treatment of Cerebral Cavernous Malformation, along with a trend towards improvement.End-of-phase 2...
Source Link
Comments